E Fund Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$518K Buy
+21,740
New +$603K 0.02% 286
2025
Q2
$233K Buy
13,675
+2,472
+22% +$43K 0.01% 344
2025
Q1
$219K Buy
+11,203
New +$293K 0.01% 350
2024
Q4
Sell
-12,020
Closed -$294K 400
2024
Q3
$294K Buy
12,020
+1,983
+20% +$51.2K 0.02% 264
2024
Q2
$235K Sell
10,037
-1,510
-13% -$37.1K 0.01% 265
2024
Q1
$382K Sell
11,547
-6,627
-36% -$206K 0.02% 232
2023
Q4
$495K Buy
18,174
+704
+4% +$17.5K 0.03% 171
2023
Q3
$420K Buy
17,470
+3,603
+26% +$96.6K 0.03% 159
2023
Q2
$443K Buy
13,867
+1,851
+15% +$60.1K 0.04% 138
2023
Q1
$368K Buy
12,016
+1,981
+20% +$78.2K 0.03% 196
2022
Q4
$392K Buy
10,035
+1,752
+21% +$78.5K 0.03% 185
2022
Q3
$395K Sell
8,283
-4,954
-37% -$283K 0.04% 185
2022
Q2
$512K Buy
13,237
+8,833
+201% +$351K 0.05% 137
2022
Q1
$252K Buy
+4,404
New +$289K 0.01% 255

Other funds holding BEAM

E Fund Management's BEAM Position: Q1 2026 in Review

E Fund Management opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 21,740 shares worth $518K. The stake represents 0.02% of the portfolio and ranks #286 among its holdings. This is a return to the name: E Fund Management previously reported a position in BEAM as recently as Q2 2025.

E Fund Management first reported a position in BEAM in Q1 2022 and has held it in 14 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • E Fund Management held 21,740 shares of Beam Therapeutics worth $518K as of Q1 2026.
  • Beam Therapeutics was a new E Fund Management position in Q1 2026.
  • Beam Therapeutics made up 0.02% of E Fund Management's portfolio in Q1 2026, its #286 holding.
  • E Fund Management first reported a position in Beam Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.